Promotion of indigenous pharmaceutical manufacturing

PLI scheme for Bulk Drugs has a total budgetary outlay of Rs. 6,940 crore

OSR Holdings moves towards major licensing deal for oral cancer immunotherapy

Under the proposed terms, Vaximm would secure a $20 million upfront payment, up to $815 million tied to clinical, regulatory, and commercial milestones

Bayer’s experimental stroke drug could reshape secondary stroke prevention

Millions of stroke survivors across the world may soon have a new defense

BioNxt secures Eurasian patent for breakthrough sublingual MS therapy

The Eurasian Patent Organization (EAPO) has granted Patent, protecting the company’s sublingual delivery technology for anticancer drugs used to treat autoimmune and neurodegenerative diseases

Neurocrine review highlights key differences between tardive dyskinesia drugs

EMA launches streamlined process to fast-track critical medicines, vaccines

The move is expected to be crucial during health crises

Indian pharma sector poised for a global leap beyond generics: K. Raja Bhanu, DG, PHARMEXCIL

With US$ 30.46 billion in exports and robust manufacturing capabilities, the industry is poised to expand into high-value drugs while strengthening ESG and compliance standards

Medico Remedies gets GMP compliance certificate from SMDC, Ukraine

SMDC is a participating authority under Pharmaceutical Inspection Cooperation Scheme (PIC/S)

ALBIS unveils next-gen healthcare materials at COMPAMED 2025

ALBIS will present a selection of advanced materials from its broad healthcare portfolio

Lupin achieves S&P Global ESG score of 91

This remarkable increase from 17 in 2021 ranks among the fastest for pharmaceutical companies, establishing Lupin as a leader in sustainable growth